Fig. 4From: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activitiesEffect of YL529 on tumor growth and survival in s. c. model. The mice bearing tumors subcutaneously were treated with YL529 or controls orally. a YL529 resulting in significant tumor growth inhibition; b Recovered tumor weights were significantly smaller in YL529 treated animals; c There was no significant difference of body weight after YL529 treated; d A significant increase in survival in YL529 treated mice was observed (Log-rank). Mean ± SEM, n = 10, *p < 0.05, **p < 0.01Back to article page